title: [Renal atheroembolic disease: evaluation of the efficacy of corticosteroid therapy].
abstract: BACKGROUND
  Even though many organs may be involved and clinical manifestations are extremely variable, a sudden worsening of renal function after vascular surgery or invasive angiographic manoeuvres is a clue for the diagnosis of renal cholesterol crystal embolization. In rare cases the disease may also occur spontaneously during anticoagulant or thrombolytic therapy. Renal atheroembolism is becoming increasingly recognized as an important cause of renal failure particularly in elderly men, and is often associated with a bad outcome. To date there is no specific and proven useful treatment apart from a few anecdotal reports on the benefits of corticosteroids.
  
  
  METHODS
  We report a group of seven patients with cholesterol atheroembolic disease presenting acute renal failure; in six patients the disease appeared after coronary arteriography and PTCA performed in the last four months, and in one patient in an apparently spontaneous form. All the patients presented cutaneous lesions, livedo reticularis, purpuric rush, necrosis of the toes; laboratory data showed an increase of acute phase proteins and eosinophilia. Results. Treatment with prednisolone was begun at a dose of 40 mg/day i.v. for four days; the dose was reduced to prednisone 0.4-0.5 mg/kg/day for 1 week, than gradually reduced further and stopped within a month. Following therapy renal function rapidly improved; clinical symptoms of malaise and abdominal discomfort subsided, with amelioration of skin lesions and cyanosis of toes.
  
  
  CONCLUSIONS
  Despite the small number of patients studied, our experience suggests that corticosteroid treatment is an effective therapeutic option in cholesterol renal atheroembolic disease, especially in the more severe cases of acute renal failure.
authors.affiliation: Divisione di Nefrologia, Arcispedale S. Anna, Ferrara, Italy. sbn@unife.it
authors.forename: N
authors.initials: N
authors.lastname: Stabellini
authors.forename: D
authors.initials: D
authors.lastname: Cerretani
authors.forename: G
authors.initials: G
authors.lastname: Russo
authors.forename: E
authors.initials: E
authors.lastname: Rizzioli
authors.forename: P
authors.initials: P
authors.lastname: Gilli
mesh_terms: D058186:Acute Kidney Injury / Q000188:drug therapy / Q000209:etiology* / Q000628:therapy; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000925:Anticoagulants / Q000627:therapeutic use; D001012:Aorta, Abdominal / Q000000981:diagnostic imaging; D001024:Aortic Valve Stenosis / Q000150:complications / Q000000981:diagnostic imaging; D018438:Blue Toe Syndrome / Q000209:etiology; D003131:Combined Modality Therapy; D017023:Coronary Angiography; D004341:Drug Evaluation; D017700:Embolism, Cholesterol / Q000150:complications / Q000188:drug therapy*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use*; D008875:Middle Aged; D011183:Postoperative Complications / Q000188:drug therapy*; D011241:Prednisone / Q000627:therapeutic use*; D006435:Renal Dialysis; D016896:Treatment Outcome; D014463:Ultrasonography; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use
chemical_list: D000893:Anti-Inflammatory Agents; D000925:Anticoagulants; D005343:Fibrinolytic Agents; D014568:Urokinase-Type Plasminogen Activator; D011241:Prednisone; D008775:Methylprednisolone